SpringWorks Therapeutics Announces Data from Phase 3 DeFi

– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – –...

Related Keywords

Germany ,United States ,Denmark ,Hanneberg ,Hessen ,Heidelberg ,Baden Wüberg ,Mannheim ,France ,Coindre ,Auvergne ,Bernd Kasper ,Samantha Hilson Sandler ,Saqib Islam ,Desmoid Working Group ,Linkedin ,Twitter ,Company To Host Virtual Investor Event On ,Nasdaq ,Time Oncology Review Program ,European Consensus Initiative ,Springworks Therapeutics Inc ,Mannheim Cancer Center ,Dana Farber Cancer Institute ,Fred Hutchinson Cancer Research Center ,Desmoid Tumor Working Group ,European Organization For Research ,European Commission ,Drug Administration ,Bone Sarcoma Group ,University Of Heidelberg ,European Society For Medical Oncology ,Nirogacestat Treatment Resulted ,Statistically Significant Improvements ,All Key Secondary Efficacy Endpoints ,Second Half ,Review Under ,Host Virtual Investor Event ,Works Therapeutics ,Presidential Symposium ,European Society ,Medical Oncology ,Chief Executive Officer ,Presentation Details ,Randomized Controlled Trial ,Nirogacestat Versus Placebo ,Progressing Desmoid Tumors ,Proffered Paper ,Principal Investigator ,Response Evaluation Criteria ,Solid Tumors ,Orphan Drug Designation ,Fast Track ,Breakthrough Therapy Designations ,New Drug Application ,Time Oncology Review ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Desmoid Working ,European Organization ,Soft Tissue ,Mayo Clinic ,Desmoid Tumors ,Report Series ,Rare Diseases ,Desmoid Tumor Working ,Nasdaq Swtx ,Springworks Therapeutics ,Nc ,